Synaptic vesicle glycoprotein 2A (SV2A)
Homo sapiens — UniProt Q7L0J3
Data last refreshed: (UniProt release unknown)
Key facts
Synaptic vesicle glycoprotein 2A (SV2A) is a protein from Homo sapiens identified by UniProt accession Q7L0J3, 742 residues long. MolForge cross-references it against 2 known binders and 192 disease associations.
- UniProt accession: Q7L0J3; gene symbol SV2A.
- Organism: Homo sapiens.
- Length: 742 amino acids.
- Approved drugs acting on it (DrugCentral): Brivaracetam and Levetiracetam.
- Top disease associations (Open Targets): epilepsy, Seizure and Bilateral tonic-clonic seizure.
- 3D structure: AlphaFold model available.
Target properties
| Protein name | Synaptic vesicle glycoprotein 2A |
|---|---|
| UniProt accession | Q7L0J3 |
| Gene | SV2A |
| Organism | Homo sapiens |
| Length | 742 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | — |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). Approved drug exists
| Druggability tier | MEDIUM |
|---|---|
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs acting on this target (2)
Approved drugs whose DrugCentral mechanism of action is this protein, most potent first.
Disease associations (192)
Diseases linked to this target (Open Targets).
- epilepsy · score 0.61
- Seizure · score 0.61
- Bilateral tonic-clonic seizure · score 0.60
- botulism · score 0.58
- neurodegenerative disease · score 0.55
- partial epilepsy · score 0.54
- status epilepticus · score 0.48
- Parkinson disease · score 0.47
- alcohol dependence · score 0.45
- polyneuropathy · score 0.39
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|---|---|---|---|
| AF-Q7L0J3-F1 | alphafold | PREDICTED | 76.78 | — |
Experimental structures are not indexed in MolForge yet — search RCSB PDB for Q7L0J3.
Amino-acid sequence (742 residues)
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
Which approved drugs target SV2A?
DrugCentral lists 2 approved drugs whose mechanism of action is SV2A: Brivaracetam and Levetiracetam.
Which diseases are associated with SV2A?
The strongest Open Targets associations for SV2A are epilepsy, Seizure, Bilateral tonic-clonic seizure, botulism and neurodegenerative disease.
How long is the SV2A protein?
The Homo sapiens SV2A protein (UniProt Q7L0J3) is 742 amino acids long.
Browse: Targets: S · all protein targets A–Z · drugs A–Z.
Sources
- UniProtKB Q7L0J3 — name, gene, function, sequence, keywords (CC BY 4.0)
- AlphaFold DB Q7L0J3 — predicted 3D structure (CC BY 4.0)
- DrugCentral — approved drugs and mechanism-of-action links (CC BY-SA 4.0)
- Open Targets Platform — disease associations and tractability (CC0)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.